Stocks Health care MRVI
NASDAQ · Health careMaravai Lifesciences Holdings, Inc. (MRVI)
Maravai Lifesciences Holdings, Inc. brought in $213M of revenue over the twelve months to September 30, 2026, up 10.7% from a year earlier. It posted a net loss of $65.7M. In fiscal 2025 capital spending exceeded operating cash flow by $70.7M. At September 30, 2026 it held $73M in cash against $147.2M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Maravai Lifesciences Holdings, Inc.
- Net worth
- Maravai Lifesciences Holdings, Inc. has a market value (market cap) of $2.1B at the latest share price, and shareholders' equity of $195.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $185.7M (-28.3% year on year), with a net loss of $130.8M. Over the 12 months to September 30, 2026: revenue $213M, net loss $65.7M.
- Cash flow
- In fiscal 2025 operations used $57.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Maravai Lifesciences Holdings, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Maravai Lifesciences Holdings, Inc. does
Maravai Lifesciences Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MRVI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $185.7M | -$130.8M | -$0.90 | -$70.7M |
| 2024 | $259.2M | -$144.8M | -$1.05 | -$22.2M |
| 2023 | $288.9M | -$119M | -$0.90 | $60.7M |
| 2022 | $883M | $220.2M | $1.67 | $518.9M |
| 2021 | $799.2M | $182M | $1.56 | $353.7M |
| 2021 | $284.1M | $89M | $2.36 | $126.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MRVI ranks in Health care
Latest SEC filings
What Maravai Lifesciences Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 10% to $45.9M versus the same quarter last year; diluted EPS -$0.09 versus -$0.18.
- November 4, 2026Exhibits 8-K
- September 29, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 8.5% to $51.4M versus the same quarter last year; diluted EPS -$0.08 versus -$0.27.
- August 6, 2026
- June 29, 2026Passive stake (5% or more) SCHEDULE 13G
- June 23, 2026Passive stake (5% or more) SCHEDULE 13G
- June 3, 2026
- May 29, 2026
Insider trades
What the people running Maravai Lifesciences Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 5 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 30, 2026 | Asarpota RajeshChief Financial Officer | Shares withheld for tax | 5,466 | $46.2K |
| October 8, 2026 | Brust BerndChief Executive Officer, Director | Shares withheld for tax | 29,250 | $217.3K |
| September 30, 2026 | Asarpota RajeshChief Financial Officer | Shares withheld for tax | 5,465 | $41.8K |
| September 8, 2026 | Brust BerndChief Executive Officer, Director | Shares withheld for tax | 29,250 | $214.1K |
| August 31, 2026 | Asarpota RajeshChief Financial Officer | Shares withheld for tax | 5,465 | $42K |
| August 10, 2026 | Brust BerndChief Executive Officer, Director | Shares withheld for tax | 29,250 | $182.2K |
| July 30, 2026 | Asarpota RajeshChief Financial Officer | Shares withheld for tax | 5,465 | $36K |
| July 8, 2026 | Brust BerndChief Executive Officer, Director | Shares withheld for tax | 29,250 | $173.2K |
Who owns MRVI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| GTCR Investment XI LLC13G, passive with 7 related filers | 51.81% | November 13, 2024 |
| Millennium Management LLC13G, passive with 2 related filers | 5.2% | September 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 178 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Gtcr LLC | 20,150,005 | 0 |
| BlackRock, Inc. | 9,970,780 | +625,512 |
| Braidwell LP | 8,702,921 | -1,537,243 |
| First Eagle Investment Management, LLC | 7,342,574 | +4,818,238 |
| 12 West Capital Management LP | 7,060,195 | -200,000 |
| Millennium Management LLC | 6,508,220 | +4,858,730 |
| Vanguard Capital Management LLC | 5,283,665 | -166,037 |
| Ophir Asset Management Pty Ltd | 4,826,698 | new |
| Renaissance Technologies LLC | 4,606,491 | +341,802 |
| Deutsche Bank AG\ | 4,304,927 | +3,446,672 |
| Geode Capital Management, LLC | 3,130,258 | +301,663 |
| State Street Corp | 2,901,706 | +472,989 |
| Nuveen, LLC | 2,857,580 | +2,627,433 |
| Jpmorgan Chase & Co | 2,593,559 | +2,236,299 |
| Two Sigma Investments, LP | 2,255,820 | +675,980 |
| Monaco Asset Management SAM | 2,231,026 | -1,189,994 |
| Prudential Financial Inc | 2,152,154 | +2,133,684 |
| Citadel Advisors LLC | 2,122,598 | +638,279 |
| Point72 Asset Management, L.P. | 2,005,579 | -1,199,917 |
| Morgan Stanley | 1,908,276 | -1,411,049 |
Insiders
11 insiders reported holding 4,744,163 shares in total, about $38M at the last price.
| Holder | Shares |
|---|---|
| Brust BerndChief Executive Officer, Director | 1,998,770466,771 held indirectly |
| Dolan ChristineSee Remarks | 425,318 |
| Eckert R AndrewDirector | 412,183 |
| Oreshack KurtGeneral Counsel | 335,767 |
| Lucier Gregory TDirector | 311,200156,077 held indirectly |
| Asarpota RajeshChief Financial Officer | 286,203 |
| Gray SusannahDirector | 216,200 |
| DeFord John ADirector | 205,478 |
| Cunningham Sean LaurenceDirector | 184,348 |
| Marker Luke JosephDirector | 184,348 |
Questions about MRVI
What does Maravai Lifesciences Holdings, Inc. do?
Maravai Lifesciences Holdings, Inc. is a company in the Health care sector, listed on NASDAQ as MRVI. Its shares trade on NASDAQ under the ticker MRVI.
What is Maravai Lifesciences Holdings, Inc.'s net worth?
Maravai Lifesciences Holdings, Inc. has a market value (market cap) of $2.1B at the latest share price, and shareholders' equity of $195.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Maravai Lifesciences Holdings, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $65.7M on revenue of $213M.
How much revenue does Maravai Lifesciences Holdings, Inc. make?
Over the twelve months to September 30, 2026 Maravai Lifesciences Holdings, Inc. reported revenue of $213M. That is 10.7% more than a year earlier.
When did Maravai Lifesciences Holdings, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Maravai Lifesciences Holdings, Inc.'s next earnings report?
Maravai Lifesciences Holdings, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare MRVI with
Follow MRVI
Get an email when Maravai Lifesciences Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Maravai Lifesciences Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.